- Home
- KZIA vs MCVT Comparison
KZIA vs MCVT Comparison
Compare KZIA & MCVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- MCVT
- Stock Information
- Founded
- KZIA 1994
- MCVT 2007
- Country
- KZIA Australia
- MCVT United States
- Employees
- KZIA N/A
- MCVT N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- MCVT Finance Companies
- Sector
- KZIA Health Care
- MCVT Finance
- Exchange
- KZIA Nasdaq
- MCVT Nasdaq
- Market Cap
- KZIA 11.7M
- MCVT 11.1M
- IPO Year
- KZIA 1999
- MCVT N/A
- Fundamental
- Price
- KZIA $8.68
- MCVT $5.28
- Analyst Decision
- KZIA Strong Buy
- MCVT
- Analyst Count
- KZIA 2
- MCVT 0
- Target Price
- KZIA $14.00
- MCVT N/A
- AVG Volume (30 Days)
- KZIA 675.5K
- MCVT 7.3M
- Earning Date
- KZIA 08-12-2025
- MCVT 08-13-2025
- Dividend Yield
- KZIA N/A
- MCVT N/A
- EPS Growth
- KZIA N/A
- MCVT N/A
- EPS
- KZIA N/A
- MCVT 0.19
- Revenue
- KZIA $1,549,158.00
- MCVT $3,246,479.00
- Revenue This Year
- KZIA N/A
- MCVT N/A
- Revenue Next Year
- KZIA $49.25
- MCVT N/A
- P/E Ratio
- KZIA N/A
- MCVT $27.43
- Revenue Growth
- KZIA 248983.08
- MCVT N/A
- 52 Week Low
- KZIA $2.86
- MCVT $1.13
- 52 Week High
- KZIA $39.05
- MCVT $8.01
- Technical
- Relative Strength Index (RSI)
- KZIA 50.61
- MCVT 69.09
- Support Level
- KZIA $7.40
- MCVT $4.30
- Resistance Level
- KZIA $10.08
- MCVT $8.01
- Average True Range (ATR)
- KZIA 0.78
- MCVT 1.07
- MACD
- KZIA -0.29
- MCVT 0.23
- Stochastic Oscillator
- KZIA 42.38
- MCVT 56.60
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About MCVT Mill City Ventures III Ltd.
Mill City Ventures III Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that the group provides are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.